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A considerable proportion of patients with cirrhosis exhibit disturbed night sleep, delayed sleep 
habits and excessive daytime sleepiness. These have been variously attributed to hepatic 
encephalopathy and impaired hepatic melatonin metabolism, but the understanding of their 
pathophysiology remains limited and their treatment problematic. Sleep is regulated by the 
interaction of a homeostatic and a circadian process. The homeostatic process determines sleep 
propensity in relation to sleep-wake history, thus the need to sleep increases with the duration of 
the waking period. The circadian process, which is marked by the 24-hour rhythm of the 
hormone melatonin, is responsible for the alternation of high/low sleep propensity in relation to 
dark/light cues. Circadian sleep regulation has been studied in some depth in patients with 
cirrhosis, who show delays in the 24-hour melatonin rhythm, most likely in relation to reduced 
sensitivity to light cues. However, while melatonin abnormalities are associated with delayed sleep 
habits, they do not seem to offer a comprehensive explanation to the disturbances in night sleep 
exhibited by these patients. Fewer data are available on homeostatic sleep control: it has been 
recently hypothesised that patients with cirrhosis and hepatic encephalopathy might be unable, 
due to excessive daytime sleepiness, to accumulate the need/ability to produce restorative sleep. 
This review will describe in some detail the features of sleep-wake disturbances in patients with 
cirrhosis, their mutual relationships and those, if any, with hepatic failure/hepatic 
encephalopathy. A separate section will cover the available information on their pathophysiology. 
Finally, aetiological treatment will be briefly discussed. 
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Sleep-wake disturbances and their assessment 
Approximately 10% of an otherwise healthy population suffers from a clinically significant sleep-wake 
disorder (1). Sleep-wake disorders are also associated with medical conditions such as cardiovascular 
disease, diabetes and depression. Difficulties sleeping can depend on the pain/discomfort associated 
with a particular disease, or can be a direct consequence of its pathophysiology. The majority of 
individuals reporting sleep-wake disturbance present with one or more of the so called ‘classical 
complaints’: i) insomnia, or a difficulty attaining and/or sustaining sleep; ii) hypersomnia or excessive 
sleepiness, which is the propensity to sleep at inappropriate times; iii) unusual events associated with 
sleep, such as heavy snoring, apnoea or limb movements. Sleep-wake evaluation begins with the 
definition of the complaint, together with a patient profile, including age, occupational/marital status 
and living arrangements. Details concerning the sleep problem are obtained, either by structured 
interviews or specific, validated questionnaires. The patient's habitual daily schedule is reviewed, 
preferably by use of sleep diaries, over a period of 2-3 weeks. Laboratory-based nocturnal 
polysomnography is considered a gold standard but is expensive, time-consuming and thus cannot be 
used for first-line assessment purposes. Wrist actigraphy is a ‘lighter’ technique, based on the 
registration of movement by means of an accelerometer, and on the assumption: sleep = no movement. 
An actigraph looks like a wristwatch and can be worn for days/weeks, without interfering with normal 
life, to assess rest-activity patterns. In recent years, it has also become common to assess a subject’s 
natural propensity to be more of a morning (lark) or an evening (owl) person/type; this is referred to as 
chronotype or diurnal preference. 
 
Sleep-wake disturbances in patients with cirrhosis 
So-called ‘sleep-wake inversion’, or the combination of restless nights and excessive daytime 
sleepiness, was first recognised as a sign of overt hepatic encephalopathy (HE) by Sherlock and 
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colleagues (2). There is also anecdotal evidence that sleep abnormalities worsen following the insertion 
of transjugular intra-hepatic portal-systemic shunts (3), and improve after initiation of treatment with 
lactulose (4). These findings have lead to the idea that the pathogenesis of sleep-wake disturbances in 
patients with cirrhosis is closely related to that of HE, and that sleep and neuropsychiatric abnormalities 
are invariably associated in these patients. There is limited evidence, however, to support this theory, 
especially in human studies. In addition, lack of sleep per se can result in neuropsychological 
abnormalities, thus potentially confounding the diagnosis of minimal/mild HE. Finally, limited attempts 
have been made to characterise sleep-wake abnormalities in patients with cirrhosis. With notable 
exceptions (5), reports have often been based on responses to unspecific sleep measures derived from 
quality of life or psychological well-being questionnaires (6). In this review, we attempt to approach 
sleep-wake disturbances in patients with cirrhosis in a descriptive fashion, without a predefined 
interpretative frame. The available evidence on their pathophysiology is also examined. 
 
Insomnia 
Insomnia seems to be considerably more common in patients with cirrhosis than in patients with other 
chronic illnesses, for example renal failure (5). Insomnia is also detected in well-compensated 
cirrhotics (5,7), with no obvious reasons for disturbed sleep such as itching, tense ascites or treatment 
with diuretics. Up to 50-65% of patients with cirrhosis complain of unsatisfactory night sleep, mostly 
in relation to difficulties falling asleep and multiple night awakenings (5-8). Questionnaire-based sleep 
complaints have been substantiated by wrist actigraphy, which documents activity over the whole 24-
hours, and frequent sleep interruptions (5,8-10). Insomnia has been traditionally associated with HE, 
and there are some experimental animal data to support this association (11-13). Regarding human 
studies, Córdoba and co-workers found no difference in the prevalence of insomnia in relation to 
psychometric performance in 44 patients with cirrhosis, 24 of whom had minimal HE (5). Montagnese 
and co-workers also observed no association between the presence of insomnia and the 
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presence/severity of HE in 87 patients, classified as neuropsychiatrically unimpaired or as having 
minimal/overt HE (7). Thus, based on the current human data, confusion between insomnia and HE 
should be avoided, especially in relation to the outcomes of treatment trials.  
 
Delayed sleep timing and diurnal preference 
Córdoba and co-workers were the first to assess sleep timing and diurnal preference in patients with 
cirrhosis, in relation to sleep quality and by comparison with healthy volunteers and patients with renal 
failure (5). An association was observed between delayed sleep habits/evening preference and impaired 
sleep quality in patients with cirrhosis, but not in the other two groups. These findings were confirmed 
by Montagnese and co-workers, who described significant correlations between diurnal preference and 
sleep quality, with evening type cirrhotic patients taking longer to fall asleep and sleeping worse than 
their counterparts with earlier sleep timing (7). The observed delays in sleep timing were shown to be 
independent of employment status in a subsequent, smaller study (9). 
It has been demonstrated that even in the healthy population, evening type people can 
experience serious difficulties when they are required to be operative in the early part of the day (14). 
Such difficulties, which may translate into morning traffic accidents and poor school/work 
performances, become particularly prominent in relation to sudden advances of the sleep-wake 
schedule, such as the spring switch to daylight-saving time or travelling eastwards across time zones 
(jet-lag East). The 60-minute delay in sleep-wake habits exhibited by patients with cirrhosis is chronic, 
rather than sudden and externally imposed. However, its effects on health/prognosis are worthy of 
further study, as circadian disruption caused by experimental, chronic jet-lag or constant exposure to 
light has been shown to promote the growth of liver tumours in laboratory animals (15).  
 
Excessive daytime sleepiness 
Profound daytime sleepiness was recognised as a sign of overt HE by Sherlock and colleagues in 1954 
(2). However, the patient population studied was small and heterogeneous, and the neurological 
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abnormalities extremely severe. Excessive daytime sleepiness has been subsequently described in 
cirrhotic patients with milder neuropsychiatric impairment (5,7,8). In at least two studies, an 
association between excessive sleepiness and the presence/degree of HE was observed (7,16). In a 
recent, large study, in which habitual daytime sleepiness was qualified as present/absent, its absence 
had a negative predictive value of 92% in relation to the occurrence of HE-related hospitalisations over 
a follow-up period of 8 months (17). Most convincingly, changes in subjective sleepiness were shown 
to closely parallel changes in blood ammonia levels in both healthy volunteers and patients with 
cirrhosis in a study of induced hyperammonaemia (18). These observations fit with the hypothesis that 
HE may be interpreted, at least to some extent, as a syndrome of decreased vigilance. Indeed, some of 
its electroencephalographic features, such as the anteriorization of the background alpha rhythm, are 
reminiscent of those observed during the transition from wake-to-sleep (19). Somewhat counter-
intuitively, there is limited evidence of a direct relationship between night sleep disturbance and 
excessive daytime sleepiness in patients with cirrhosis, suggesting that their occurrence may indeed 
reflect different disease processes (7).  
 
The data presented refer to a sort of ‘old-fashioned’, archetypical patient with alcohol-related or viral 
cirrhosis. However, the incidence of non-alcoholic steatohepatitis (NASH)-cirrhosis is increasing 
dramatically, and given its association with overweight, diabetes, systemic hypertension and 
obstructive sleep-apnea, a considerably more complex picture will probably need to be built in the 
future. Evidence in this respect is starting to emerge, for example with: i) a brief report highlighting an 
association between loss of slow-wave sleep and reduced levels of ghrelin in a small group of cirrhotic 
patients with minimal HE (20), and ii) a recent study comparing the polysomnographic characteristics 
of patients with obstructive sleep-apnea with and without cirrhosis (21).  
 
Physiological sleep-wake regulation  
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The currently accepted model of human sleep-wake regulation postulates that two primary components 
regulate sleep: a circadian  process, with near-24-hour periodicity, and a homeostatic process that 
builds up during wakefulness and declines during sleep (Figure 1A) (22).  
 
Circadian sleep-wake regulation 
Circadian regulation is responsible for the alternation of periods of high/low sleep propensity, in 
relation to the endogenous timing system and external dark/light cues, and irrespective of preceding 
sleep-wake behaviour. The suprachiasmatic nuclei (SCN) of the hypothalamus are the site of the so-
called master circadian clock, which generates the SCN-driven circadian rhythms of melatonin, cortisol 
and core body temperature. In humans, the average, endogenous circadian period is slightly longer than 
24 hours, and it is constantly synchronised to the 24-hour day by external influences. Light is the major 
external time cue and it reaches the SCN by afferent projections from the retina, via the retino-
hypothalamic tract. In turn, the SCN project to the pineal gland via a multisynaptic pathway, regulating 
the production of melatonin. Melatonin can be thought of as the neuroendocrine transducer of the 
light/dark cycle. Thus, in healthy individuals, its synthesis increases soon after the onset of darkness, 
peaks in the middle of the night, and then gradually declines. The nocturnal rise in melatonin synthesis
 
is associated with an increased propensity to sleep and is acutely suppressed by light exposure. 
Melatonin is mostly hydroxylated and sulphated to 6-sulphatoxymelatonin (aMT6s), primarily via the 
liver cytochrome CYP1A2 (23), and aMT6s is subsequently excreted in the urine.  
The genetics of circadian timing 
The current model for the circadian timing system encompasses a number of clock genes. These encode 
for proteins directly involved in the molecular mechanism which produces a circadian oscillation. The 
oscillation is generated autonomously in each of the ≈ 20,000 neurons clustering within the human 
SCN (24). Single cell oscillations become synchronised and give rise to a robust, circadian molecular 
mechanism which acts as a ‘master clock’. In turn, this controls the activity of several, so-called clock-
8 
 
controlled genes. At the core of the circadian clockwork are a number of overlapping transcriptional-
translational feedback loops, which comprise positive and negative interconnected arms (25). In a 
simplified, schematic description of the mammalian circadian machinery, the transcriptional activator 
proteins BMAL and CLOCK (CLK) form heterodimers which bind to specific elements (E-boxes) 
located within the promoter regions of the clock genes Period (Per) and Cryptochrome (Cry), and 
activate their transcription. There are three Per paralogs (Per1, Per2, and Per3) and two Cry paralogs 
(Cry1 and Cry2) in mammalian genomes. The subsequent translation of the corresponding mRNAs into 
proteins is accompanied by a number of post-translational modifications, which result in a lag of about 
4-6 hours between transcription and protein accumulation, and are crucial to sustain rhythmicity. Once 
PER and CRY proteins start to accumulate, they form PER/CRY heterodimers, which enter the nucleus 
and negatively feed-back to the CLK/BMAL heterodimers, thus inhibiting their own transcription. The 
entire process requires about 24 hours, and is efficiently synchronized to the period of the earth rotation 
by day/night natural cycles and other environmental cues. Mutations and polymorphisms in the clock 
genes have been implicated in diurnal preference/circadian disorders (26) and are thought to represent a 
risk factor for the development of sleep-wake disturbances in a number of medical conditions, 
especially psychiatric disorders (27).  
Peripheral clocks and the liver 
In 1972, Langner and co-workers observed that oxygen consumption in a rat liver suspension culture 
exhibited circadian oscillations (28). This observation paved the way to the demonstration of the 
existence of circadian clocks other than the master SCN one. These clocks are referred to as 
‘peripheral’, and they are present in virtually every organ and tissue, including the liver, the muscle, the 
kidney and the hearth (29). When isolated, these tissues maintain robust circadian rhythms of gene 
expression, which persist in vitro for several days, indicating that the SCN are not required for short-
term rhythmicity (30). However, the SCN master clock is the only clock directly driven by light and 
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plays a hierarchical role, determining both the phase and synchrony of clock gene expression in 
peripheral clocks. Synchronization of peripheral clock timing occurs via the autonomic nervous system, 
hormone metabolites and metabolic pathways. In addition, cues such as feeding patterns, temperature 
cycles and physical activity can also reset/phase-shift peripheral oscillators (24). It is believed that 
peripheral clocks are crucial in regulating specific physiological and metabolic features of most tissues, 
such as energy metabolism and nutrients processing/storage. For example, disruption of the liver clock 
results in abnormal glucose and elevation of serum liver enzymes (31). Nonetheless, the molecular 
links between the metabolic rhythms produced by feeding/fasting, and the resetting of peripheral clocks 
have represented a puzzle for several years. Recently, it has been demonstrated that metabolic cycles 
can directly cross-talk to the molecular components of the peripheral circadian clock within the mouse 
liver (32). In more detail, feeding/fasting cycles are able to locally modify some of the molecular 
features of crucial clock proteins, thus synchronizing the local clock to their periods and uncoupling it 
from SCN control. Some of the molecules involved have been identified as the NAD-dependent 
enzymes Sirtuin1 (SIRT1) (33) and the poly ADP-ribose polymerase-1 (PARP-1), which act as NAD 
sensors and feedback directly to the core of the liver circadian clock. SIRT1 is a histone deacetylase 
and it induces CLK-mediated chromatin epigenetic modifications which, in turn, inhibit Per and Cry 
transcriptional activity. PARP-1, which is also involved in chromatin remodelling, adds ADP-ribose 
molecules to CLK, reducing its binding to the E-boxes and thus modifying the phase of Per and Cry 
transcription. Chromatin remodelling is fundamental for the control of a large number of nuclear 
processes. The above mentioned findings have connected cellular metabolism, epigenetic status, and 
the circadian clock (34). Finally, an emerging mechanism contributing to the fine tuning of circadian 
rhythmicity within the liver clock involves specific miRNAs, which have been shown to downregulate 
or silence circadian genes expression (35). 
 
Homeostatic sleep-wake regulation 
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Homeostatic regulation is responsible for the progressive increase in sleep propensity during the 
waking hours, and its dissipation during sleep. The pioneering studies of Blake and Gerard showed that 
both the arousal threshold and the dominance of slow electroencephalographic waves are high in the 
initial part of night sleep, and progressively decrease (36). This was confirmed in subsequent studies, 
and it was also demonstrated that sleep deprivation produces an increase in slow-wave activity in the 
following ‘recovery’ night. By contrast, a daytime nap attenuates slow-wave activity in the subsequent 
sleep episode (37). These findings indicate that slow-wave activity reliably reflects prior history of 
sleep and wake. The exact neurochemical correlates of human sleep homeostasis remain unknown, but 
there is evidence that adenosinergic neurotransmission might play a crucial role (38).  
 
Sleep-wake regulation in patients with cirrhosis  
Circadian sleep-wake regulation 
As melatonin is metabolised in the liver, it has generally been assumed that in patients with cirrhosis its 
clearance would be delayed, or somehow compromised. There is evidence to support this contention, as 
patients with cirrhosis show high daytime melatonin levels (39,40), low urinary aMT6s (41), and a 
reduction in the clearance of exogenously administered melatonin (42). In a study where plasma 
melatonin and urinary aMT6s were assessed simultaneously over a 36-hour period in strictly controlled 
laboratory conditions, 24-hour melatonin clearance was comparable to that of healthy controls, while 
overnight melatonin clearance was reduced (43). In the same and other studies, correlations were 
observed between the delay in the timing of melatonin/aMT6s peaks and the degree of hepatic failure 
(9,43-45). However, other circadian abnormalities have also been described, such as delays in the 
nocturnal rise of melatonin and in its time to peak (39,43,45), which suggest dysfunction of the central 
SCN circadian clock. The functional integrity of the retinal-hypothalamic axis, and thus of the SCN 
clock, can be assessed by measuring light-induced ‘melatonin suppression’ [i.e. the rapid decrease in 
melatonin levels in response to  ocular light exposure at night] and/or by measuring the 24-hour profile 
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of at least two variables out of melatonin, cortisol and core body temperature. Montagnese and co-
workers demonstrated parallel delays in the onset of melatonin and cortisol rhythms, and attenuated 
melatonin sensitivity to light in a group of 20 patients with cirrhosis, supporting the hypothesis of 
central circadian dysfunction (43,46). Other authors (45) reported normal cortisol rhythms in patients 
with cirrhosis but the number of timed samples was possibly smaller than that required for accurate 
estimates of rhythm timing, and the confounding effect of light was not controlled for. In the study by 
Montagnese and co-workers, melatonin sensitivity to light at night was inversely correlated with the 
timing of the melatonin peak (43), supporting Steindl’s original hypothesis that the observed delays in 
the 24-hour melatonin profile depend on a dysfunctional retinal-hypothalamic axis (39,47).   
Some attempt has been made to correlate the changes in the endogenous melatonin rhythm with 
the sleep disturbances observed in patients with cirrhosis, but the findings have been inconclusive 
(39,43). It has been suggested that circadian rhythm delays may be associated with delayed sleep 
habits, although not necessarily with impaired sleep quality alone (9). The combination of evening 
preference, delayed sleep habits, impaired sleep quality and delayed circadian rhythms is reminiscent 
of delayed sleep phase syndrome (DSPS), a circadian rhythm sleep disorder characterised by 
considerable delays in sleep onset/wake times. The goal of treatment for DSPS is to resynchronise the 
circadian clock with the 24-hour light/dark cycle, and the advancing effect of exposure to bright light in 
the morning has been shown to be beneficial (48). One encouraging case report suggests that treatment 
with morning light might be effective in managing the DSPS-like syndrome observed in patients with 
cirrhosis (49). 
Homeostatic sleep-wake regulation 
Less information is available on sleep homeostasis in patients with cirrhosis. Polysomnography has 
been performed in a limited number of studies, mostly with the aim of evaluating indices of HE rather 
than sleep homeostatic indices per se. Correlations have been established between the clinical severity 
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of encephalopathy and ammonia levels on one hand, and the degree of disruption of sleep architecture 
on the other (50, 20). More recently, nap polysomnography was obtained in a group of patients with 
cirrhosis and matched controls, at baseline and after the induction of mild hyperammonaemia (18). 
Hyperammonaemia resulted in increased subjective sleepiness in both groups. However, it led to longer 
and deeper sleep in healthy volunteers and to shorter, more superficial sleep in cirrhotic patients, 
pointing to a reduced ability to produce restorative sleep (18). Finally, decreased density of the 
adenosine receptor A1AR has been described in both cortical and sub-cortical regions of the brain of 
cirrhotic patients (51), also implicating impaired homeostatic regulation in their sleep-wake 
abnormalities.  
 
A model for the interaction and the effects of circadian and homeostatic dysfunction in cirrhosis is 
presented in Figure 1. This is a simple model based on the current available evidence. However, there 
are multiple, mostly unexplored mechanisms through which cirrhosis and its complications might affect 
sleep-wake patterns and circadian regulation; these are presented in Figure 2. 
 
Treatment of sleep-wake disturbance in patients with cirrhosis 
Limited data are available on how we should treat sleep-wake disturbances in patients with cirrhosis. 
This is because sleep-wake assessment is not part of routine hepatological practice, the understanding 
of the pathophysiology is limited, and these patients are fairly sensitive to psychoactive medication. 
Even when an ‘aetiological’ treatment was attempted by Spahr and colleagues, who administered the 
histamine H1 blocker hydroxyzine to patients with minimal HE and sleep impairment, some risk of 
precipitating severe HE was observed (10). The combination of the above issues has resulted in under-
diagnosis and cautious, aspecific and potentially inappropriate management. The data currently 
available allow formulation of the following, simple recommendations: 
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i) Routine assessment of sleep quality, sleep timing and daytime sleepiness should be performed 
(52).  
ii) The detection of excessive daytime sleepiness should prompt search for and treatment of 
hyperammonaemia and HE (17). 
iii) Sleep and light hygiene practices should be encouraged, to include regular sleep-wake schedules, 
exposure to bright light in the early hours of the morning and avoidance of bright light exposure in 
the evening (DSPS-like treatment). Given the observed impairment in overnight melatonin 
clearance, the benefits and risks of melatonin administration are worthy of specific, formal studies.    
iv) Hypnotics should be used with caution, especially in decompensated patients. No formal trial data 
are available. However, it is reasonable to assume that the hypnotic of choice should have: 
negligible hepatic metabolism, short half-life, no active metabolites and limited lipophilia, to avoid 
prolonged intra-cerebral action. These features should not limit its usefulness, as difficulties falling 
asleep are considerably more common than early awakening in this patient population.    
However, it is only further elucidation of the pathophysiology of sleep-wake abnormalities in patients 
with cirrhosis that may lead, in time, to the development of specific treatment strategies. Over the last 
few decades, chronobiologists and sleep scientists have taken an interest in the liver, and they have 
been rewarded with remarkable discoveries. Hepatologists should try to reciprocate, both for the sake 
of their patients and their research: there is a liver clock, and it may soon be liver time.  
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Legends to Figures 
Figure 1. Cirrhosis-associated abnormalities in the two-process model of sleep regulation. A. Normal 
interaction between the circadian oscillation in sleep propensity and the increase in homeostatic sleep 
pressure during the waking hours: the greater the distance between the two curves (23:00), the higher 
the sleep propensity (22). B. Abnormal interaction between the homeostatic regulation (black line) and 
the delayed circadian rhythm (red dotted line) in a patient with cirrhosis; grey line: reference circadian 
oscillation in the healthy population. The lack of synchrony between the two processes leads to a jet-lag 
East/DSPS-type sleep disorder, which could contribute to the observed difficulties in commencing 
(increased latency) and maintaining sleep (fragmentation). C. Abnormal interaction between blunted 
homeostatic fluctuations (red broken line) and shifted/delayed circadian rhythm (red dotted line) in a 
patient with cirrhosis and HE; grey lines: reference circadian oscillation and homeostatic build-up in 
the healthy population. Hyperammonaemia/HE-related daytime somnolence may compromise the 
homeostatic build-up of sleep pressure during the daytime hours, thus contributing to a reduction in 
slow-wave, restorative sleep.   
 
Figure 2. Hypothetical, largely unexplored pathways through which cirrhosis and its complications 
may lead to sleep-wake and circadian rhythm abnormalities: A. In compensated cirrhosis, subverted 
liver architecture/vascularisation may lead to dysfunction of the hepatic clock. In addition, the reduced 
ability of the liver to store glycogen and synthesise protein may impinge on the physiological, rhythmic 
changes in glucose/protein metabolism which anticipate and follow meals. B. In decompensated 
cirrhosis, sympathetic/parasympathetic imbalance may compromise the autonomic transmission of the 
circadian SCN clock signal to the periphery. In the same context, the combination of hyperdynamic 
circulation, peripheral vasodilatation and temperature deregulation may impinge on the vascular 
mechanisms implicated in sleep preparation/sleep onset. In addition, malnutrition and muscle loss may 
lead to both reduced exercise and blunted response to exercise cues. C. Finally, the presence of HE per 
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se, which reduces alertness, might weaken the wake-sleep cycle and compromise the build up of 
homeostatic sleep pressure. In addition, abnormalities in ocular or cerebral light/dark perception or 
interpretation might alter the phase of the central SCN circadian clock.   
CNS: Central Nervous System; SCN: Suprachiasmatic nuclei 
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